slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 26,911-26,940
Pages 1,349
Rows per page 30
Beat
26,911-26,940 of 40,452
18
The slide uses a split-layout: a table for AUM breakdown by asset class on the left and a timeline of team additions on the right.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · TeamLoop · Hypothesis Test1 hit
28
The diagram uses a hub-and-spoke circular flow model to represent capital allocation.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
29
The slide uses a combination of grouped bar charts and a line chart to illustrate segment performance and total adjusted operating margin.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
30
The slide presents two distinct charts: a combo chart for financial ratios and a stacked bar chart for headcount.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
31
The chart shows a debt maturity ladder alongside cash and undrawn revolver availability.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
32
The chart uses a stacked bar format for capital returns and a separate line/box format for net income.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
33
The slide highlights capital allocation strategy via dividends and buybacks.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
05
The chart highlights Carvykti's superior growth curve in its first six quarters compared to the peer set.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
13
The slide uses a color-coded system to indicate geographic focus (Global, US, China) for each clinical trial program.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · Product1 hit
10
The slide uses a categorization framework to illustrate the studio's production strategy across four distinct risk/reward segments.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
11
Slide 11 of a Lionsgate presentation.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
12
Includes a navigation bar at the top indicating this is part of a larger presentation.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
13
The slide uses a three-part narrative structure: investment, acquisitions, and financial outcome.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
20
Includes detailed footnotes explaining the valuation and ownership calculations.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · FinancialsLoop · Why Now1 hit
21
Includes specific footnotes regarding non-GAAP measures and eOne acquisition adjustments.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · FinancialsLoop · Why Now1 hit
22
The chart uses a waterfall structure to bridge gross debt to allocated net debt for Lionsgate Studios.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · FinancialsLoop · Why Now1 hit
25
Includes headshots, professional summaries, and a grid of logos representing past company affiliations.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market Size1 hit
19
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Team1 hit
20
The slide uses a grid layout to present 10 advisors, each with a headshot, name, role, and company logo.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Team1 hit
16
The model is explicitly labeled as 'Razor/Razor Blade Economics'.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
17
Uses the 'Razor/Razor Blade' business model framework.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
03
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Team1 hit
15
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
16
The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit